Most Recent
H.J. Heinz Company has dropped its appeal of a ruling that it marketed its sugary snacks to kids as healthy, after the ACCC won a fraction of the $10 million fine it sought for the consumer law violations.
Motorola has slammed an attempt by Hytera Communications to limit discovery in a long-running patent dispute between the companies, saying documents withheld by the Shenzen-based radio manufacturer come nowhere close to being state secrets protected under Chinese law.
Failed digital ad company Unlockd has until the end of the month to set out its competition case against Google or the suit will be thrown out.
Decorated war hero Ben Roberts-Smith wants to suppress Fairfax's defence in a highly contentious defamation case, saying the media company wanted the "scandalous and vexatious" document public so it could report on it.
A judge has granted a unit of Queensland Investment Corporation's request for a confidentiality regime for certain documents discovered in an ongoing legal spat with EnergyAustralia over the $1.78 billion sale of a gas facility in Victoria, but said three EnergyAustralia can view the documents.
The law firm leading a shareholder class action against Crown Resorts wants evidence from employees whose arrest in China during a 2016 government crackdown on gambling sent the company's stock price tumbling.
Hytera Communications wants the Federal Court to block Motorola from accessing evidence in their patent war covered by Chinese laws prohibiting disclosure of state secrets or compromising the country's cybersecurity.
A Gold Coast-based derivatives trading firm has lost a defamation case against an online investment forum over critical comments warning potential investors against using the company.
A judge has shot down a last minute bid by an insurance brokerage facing a cross claim in a class action over failed debenture issuer Provident Capital to retract an admission in its defence ahead of trial next month.
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.